The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Entirely predictable given the current febrile market and they did miss their target. It will settle back down and at least the reason for some of the lower profits was increased R&D expenditure ie. Reinvesting profits for future growth.
Bit annoying to see the lack of dividend growth - but not been through the results in detail
Annual results really warrant a drop of over £ 2.50 a share ?
I remember when these boards were awash with indignation at government intervention aimed at discouraging AZN institutional shareholders from backing the Pfizer takeover bid at £55 per share. Let the market work it's magic they said, take the money and run etc. ad nauseum. Well what a difference there is now. Pfizer down 60% from its Covid vaccine highs and now a recovery play. Meanwhile AZN (which virtually gave away it's Covid19 vaccine at cost) is sitting stable at almost double the bid price and with it's oncology pipeline the envy of others. LOL
Not sure if the movements up and down between 102-108 is a sign of lost direction over last 6months.
Remember this SP rocketed on back of COVID, just like ROG.SW.
I think this has been a sell for last month or two.
There is good NEWS, but it’s not news we need its results and gains from this.
There is one out of 12 brokers that has a £134 target, others £100-£108.
If you have a look further afield there are better options that will outperform this bluechip.
Don’t just invest solely in UK chips…
GLA
Astrazeneca is looking more like a Takeover target by the day.
Apparently because AZN is uniquely vulnerable to the lower drug price ceilings introduced by Biden’s Inflation Reduction Act? Why on earth this should be the case is beyond me. Go figure, LOL
Odd that UBS has reduced price target and Morgan Stanley has raised it. Market seems to be listening to UBS!
Times mention, for what it’s worth:
https://www.thetimes.co.uk/article/b75077c7-c28c-4a6b-afcf-cb978ed28d3d
Looking back one year later, I could buy back last slice 9% cheaper now .
Did not sell at the top either which was 12,294 on 24/4/23.
The low one month ago 9,900 on 29/11/23.
BARRON'S ( whoever they are say good buy now )
BIOTECH AND PHARMA
BARRON'S STOCK PICK
Buy AstraZeneca Stock. It Looks Much Better Going Into 2024.
By Teresa Rivas Dec 28, 2023
Big pharmaceutical companies create the medications that keep countless people around the world healthy, but that hasn’t helped their ailing stock prices this year. The United Kingdom-based AstraZeneca has been no exception, but its shares could get a shot in the arm in 2024.
Nirsevimab the successful new vaccine for babies to prevent pneumonia has just been rolled out in the US and Spain. Produced by Sanofi and AZN. Should boost the SP.
Looks like AZ has followed suit and added small Gracell to its portfolio for a mere $1.2bn.
It is about $1bn when Gs cash is taken off.
Probably cheaper than licensing in the long run…
Added, small.
'R&D success gives AstraZeneca a shot in the arm', they said.
..
Now I am worried!
Tipped as a “buy” in today’s Questor column Daily Telegraph.
All of the Covid vaccine producing companies were granted legal indemnity.
Scientists have drawn a link between the Oxford-AstraZeneca vaccine and a “spike” in cases of a rare disease that can leave its victims paralysed.
Three separate studies reported an increase in Guillain-Barré syndrome (GBS) shortly after the roll out of the AstraZeneca vaccine.
https://www.msn.com/en-gb/health/other/astrazeneca-vaccine-linked-with-spike-in-cases-of-rare-disease-that-can-paralyse-victims/ar-AA1ldmba
Not so good news, Is it?
Can you imagine the payouts and the legal costs?
Not so fast perhaps. Could slip back to £100. Depends on mood for FTSE 100
Bought a nice 166 shares today - She's going up!
Sorry mate.
Didn't understand what you was saying.
A bit cryptic for me. I'm from Yorkshire & we just say it how it is. :-)
Now is the time to buy!
"Confused" is a tad overgenerous given his previous post regarding "A string of failures lately". Math is obviously another weak point. One to file under "ignore" LOL
Added 200 more shares here this morning. Future is bright.